Eiko lifesciences Limited successfully concluded its first Extra-Ordinary General Meeting (EOGM) on January 7, 2026, with shareholders approving two significant special resolutions related to preferential share issuance. The meeting was conducted at 3:00 PM IST through video conferencing in compliance with the Companies Act, 2013 and relevant regulatory circulars.

Meeting Overview and Participation

The EOGM witnessed active participation from shareholders across categories. A total of 21 shareholders attended the meeting through video conferencing, comprising 5 promoters and promoter group members and 16 public shareholders. The company had 3,186 total shareholders on the record date of January 2, 2026.

Voting Process and Timeline

The voting process was conducted through both remote e-voting and e-voting during the meeting. Remote e-voting commenced on January 4, 2026, at 9:00 AM IST and concluded on January 6, 2026, at 5:00 PM IST. Additionally, e-voting facility was provided during the EOGM and extended up to 15 minutes after the meeting's conclusion. The scrutinizer's report was prepared by Shravan A. Gupta, Practicing Company Secretary, who was appointed by the Board of Directors on December 11, 2025.

Resolution 1: Warrant Issuance Approval

The first special resolution for the issuance of 33,00,000 warrants convertible into equity shares on preferential basis received overwhelming support from shareholders.

The resolution was approved with 28 voters supporting and only 1 voter opposing. Notably, 5,148,842 votes from promoters and pre-preferential holders were considered invalid as they were interested parties in the resolution.

Resolution 2: Equity Share Issuance Approval

The second special resolution for the issuance of 6,75,000 equity shares on preferential basis also received strong shareholder approval.

This resolution was supported by 27 voters with 2 voters opposing. Similar to the first resolution, votes from promoters and pre-preferential holders totaling 5,148,842 were treated as invalid due to their interest in the resolution.

Regulatory Compliance and Documentation

The company ensured full compliance with regulatory requirements under Regulation 44 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The voting results and scrutinizer's report were submitted to BSE Limited on January 9, 2026, with scrip code 540204. The electronic notice and explanatory statements were distributed to shareholders on December 11, 2025, with appropriate provisions for shareholders without registered email addresses.

Conclusion

Both special resolutions were passed with the requisite majority, enabling Eiko LifeSciences Limited to proceed with its capital raising plans through preferential issuance. The high approval rates of 99.9999% for both resolutions demonstrate strong shareholder confidence in the company's strategic initiatives. The successful conduct of the EOGM through digital means reflects the company's adherence to modern governance practices while maintaining transparency and regulatory compliance.

Eiko LifeSciences has informed the stock exchanges about a regulatory penalty imposed on its promoter group entity by the Securities and Exchange Board of India (SEBI). The disclosure, made under Regulation 30 of SEBI's Listing Obligations and Disclosure Requirements, reveals significant compliance issues within the promoter group structure.

SEBI Penalty Details

The regulatory action centers on M/s. Lenus Finvest Private Limited, a promoter group entity of Eiko LifeSciences. SEBI issued an adjudication order dated January 5, 2026, imposing a monetary penalty for regulatory violations spanning nearly two years.

Nature of Regulatory Violation

The SEBI order addresses alleged non-compliance with Regulation 31 of the Substantial Acquisition of Shares and Takeovers (SAST) Regulations. The specific violation relates to non-disclosure of margin pledge requirements by the concerned Depository Participant during the specified transaction period. This type of violation typically involves inadequate disclosure of pledged securities, which can impact transparency in shareholding patterns and market information.

Financial and Operational Impact

Eiko LifeSciences has explicitly stated that the regulatory penalty will not create any financial burden on the company itself. The penalty amount of ₹1.00 lakh is relatively modest and pertains solely to the promoter group entity's actions rather than the listed company's operations.

Promoter Group Response Strategy

The promoter group entity has indicated its intention to challenge the SEBI adjudication order through available legal channels. M/s. Lenus Finvest Private Limited plans to explore all options to contest the regulatory decision and will take appropriate action in due course. This response suggests the promoter group may dispute either the nature of the violation or the penalty amount imposed.

Regulatory Compliance Framework

The disclosure follows SEBI's Master Circular SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, which mandates comprehensive reporting of regulatory actions affecting listed entities and their associated parties. This transparency requirement ensures that investors and stakeholders remain informed about compliance issues that could potentially affect corporate governance standards, even when the direct financial impact on the listed entity remains minimal.